Tier 4 — mechanistic

NAD + Precursors in Human Health and Disease: Current Status and Future Prospects

Yaku K, Nakagawa T
Antioxidants & redox signaling 2023 39; 16-18; 1133-1149

Bibliography

PubMed
PMID 37335049
DOI
10.1089/ars.2023.0354
Funding
Funding details are not specified in the accessible publication information.
Competing interests
A complete competing-interest declaration is not specified in the accessible publication information.

Study snapshot

DesignNarrative evidence review
ModelPublished mechanistic and clinical literature
SampleNR, NMN and NAD+ metabolism literature
InterventionReview of precursor biology and translation
DurationPublished 2023 review
EndpointsEvidence synthesis and translational limitations

What the study showed, in plain terms

The review discussed clinical target engagement, modest efficacy relative to preclinical expectations and the role of host–microbiome interactions.

Key findings

The review discussed clinical target engagement, modest efficacy relative to preclinical expectations and the role of host–microbiome interactions.

What this study can and cannot tell us

Narrative synthesis and mechanistic hypotheses do not establish a treatment effect or one universally optimal precursor.

Related papers in the corpus

Tier 4
Emerging strategies, applications and challenges of targeting NAD + in the clinic
Zhang J et al. · Nature aging · 2025
Tier 4
What is really known about the effects of nicotinamide riboside supplementation in humans
Damgaard MV et al. · Science advances · 2023
Tier 4
Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions
Freeberg KA et al. · The journals of gerontology. Series A, Biological sciences and medical sciences · 2023
Tier 4
Balancing NAD + deficits with nicotinamide riboside: therapeutic possibilities and limitations
Cercillieux A et al. · Cellular and molecular life sciences : CMLS · 2022
Tier 1
Effects of NAD+ precursor supplementation on glucose and lipid metabolism in humans: a meta-analysis
Zhong O et al. · Nutrition & metabolism · 2022
Tier 4
Preclinical and clinical evidence of NAD + precursors in health, disease, and ageing
Reiten OK et al. · Mechanisms of ageing and development · 2021

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology